Skip to main content
. 2021 Dec 10;11(1):223–235. doi: 10.1007/s40120-021-00303-x

Fig. 3.

Fig. 3

Prescription changes in patients treated with erenumab (a) and in controls (b) in 12 months pre-index (white) and in 12 months post-index (gray shading) P values (12 months pre-index vs. post-index) for medication groups based on prescriptions